Year None20232022202120202019201820172016 Date Latest Press Release September 12, 2023 Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta August 14, 2023 Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update June 29, 2023 Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO June 28, 2023 Eiger BioPharmaceuticals to Host Business Update Call Tomorrow May 11, 2023 Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update May 3, 2023 Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) April 13, 2023 Eiger BioPharmaceuticals Strengthens Management Team with New Appointments March 16, 2023 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update February 8, 2023 New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 December 15, 2022 Eiger BioPharmaceuticals Announces Leadership Change Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
